Milestone Pharmaceuticals Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Milestone Pharmaceuticals Inc. (MIST) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $4.79 per share for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2021-05-17
- Milestone Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $4.79, a 68.47% decline year-over-year.
- Milestone Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2020-03-31 was $15.19, a 128.42% increase year-over-year.
- Milestone Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2019-03-31 was $6.65, a 331.09% increase year-over-year.
- Milestone Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2018-03-31 was $1.54.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month |
|---|---|---|---|---|---|
| 2021-03-31 | $4.79 10-Q · filed 2021-05-17 | ||||
| 2020-09-30 | $9.14 10-Q · filed 2020-11-13 | ||||
| 2020-06-30 | $9.14 10-Q · filed 2020-08-12 | ||||
| 2020-03-31 | $15.19 10-Q · filed 2020-05-14 | ||||
| 2019-09-30 | $11.76 10-Q · filed 2019-11-13 | ||||
| 2019-06-30 | $7.85 10-Q · filed 2020-08-12 | $7.85 10-Q · filed 2019-08-13 | |||
| 2019-03-31 | $6.65 10-Q · filed 2020-05-14 | $9.42 10-Q · filed 2019-06-19 | |||
| 2018-09-30 | $1.13 10-Q · filed 2019-11-13 | ||||
| 2018-06-30 | $1.11 10-Q · filed 2019-08-13 | ||||
| 2018-03-31 | $1.54 10-Q · filed 2019-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |